ERBB2 and breast carcinoma: Meanwhile, an analysis of three pooled studies [88, 102, 109] on the effect of HER2 on pCR outcome in anthracycline-treated breast cancer patients revealed that patients with HER2− biomarker were significantly more likely to achieve pCR (OR 2.31; 95% CI 1.42–3.75; p=0.0008; Fig. 4E).